Pharnext: Consolidation Of Shares Making Up Its Share Capital

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds Regeneron

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds share price

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds analyst

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln eur was without COPD * Drug could be first new COPD treatment in over decade (Adds Dupixent sales,

March 23 (Reuters) - Poxel Sa: * POXEL ANNOUNCES CASH RUNWAY EXTENDED THROUGH Q2 2025 BASED UPON DEBT RESTRUCTURING AGREEMENT AND NEW EQUITY-LINKED FINANCING FACILITY * COMPANY EXPECTS THAT ITS

(Releads, adds background on Dupixent) By Ludwig Burger and Juby Babu March 23 (Reuters) - Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat "smoker's lung", giving a major

March 23 (Reuters) - Poxel SA: * POXEL REPORTS FINANCIAL RESULTS FOR FULL YEAR 2022 AND PROVIDES CORPORATE UPDATE * POXEL REPORTED REVENUES OF EUR 0.674 MILLION FOR YEAR ENDED DECEMBER 31, 2022, * NET

March 23 (Reuters) - Sanofi SA: * SANOFI-DUPIXENT SHOWS REDUCTION IN EXACERBATIONS IN PHASE 3 TRIAL AS A POTENTIAL TREATMENT FOR COPD * SANOFI-PHASE 3 TRIAL OF DUPIXENT SHOWED SIGNIFICANT REDUCTION (

March 23 (Reuters) - Innate Pharma SA: * CASH POSITION OF EUR 136.6 MILLION AS OF DECEMBER 31, 2022 * REVENUE AND OTHER INCOME FROM CONTINUING OPERATIONS AMOUNTED TO EUR 57.7M IN 2022 (2021: EUR 24.7M

March 23 (Reuters) - Valneva SE: * VALNEVA REPORTS FULL YEAR 2022 RESULTS AND PROVIDES CORPORATE UPDATES * STRONG CASH POSITION OF EUR 289.4MILLION AT DECEMBER 31, 2022 * TOTAL REVENUES OF EUR 361.3